vs
Side-by-side financial comparison of ENTEGRIS INC (ENTG) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $823.9M, roughly 1.8× ENTEGRIS INC). ENTEGRIS INC runs the higher net margin — 6.0% vs 4.4%, a 1.6% gap on every dollar of revenue. On growth, BeOne Medicines Ltd. posted the faster year-over-year revenue change (32.8% vs -3.1%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $134.0M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 3.4%).
Entegris, Inc. is a supplier of materials for the semiconductor and other high-tech industries. Entegris has approximately 8,000 employees throughout its global operations. It has manufacturing, customer service and/or research facilities in the United States, Canada, China, Germany, Israel, Japan, Malaysia, Singapore, South Korea, and Taiwan. The company’s corporate headquarters are in Billerica, Massachusetts.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
ENTG vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $823.9M | $1.5B |
| Net Profit | $49.4M | $66.5M |
| Gross Margin | 43.8% | 90.5% |
| Operating Margin | 12.7% | 12.4% |
| Net Margin | 6.0% | 4.4% |
| Revenue YoY | -3.1% | 32.8% |
| Net Profit YoY | -51.7% | 143.8% |
| EPS (diluted) | $0.33 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $823.9M | $1.5B | ||
| Q3 25 | $807.1M | $1.4B | ||
| Q2 25 | $792.4M | $1.3B | ||
| Q1 25 | $773.2M | $1.1B | ||
| Q4 24 | $849.8M | $1.1B | ||
| Q3 24 | $807.7M | $1.0B | ||
| Q2 24 | $812.7M | $929.2M | ||
| Q1 24 | $771.0M | $751.7M |
| Q4 25 | $49.4M | $66.5M | ||
| Q3 25 | $70.5M | $124.8M | ||
| Q2 25 | $52.8M | $94.3M | ||
| Q1 25 | $62.9M | $1.3M | ||
| Q4 24 | $102.2M | $-151.9M | ||
| Q3 24 | $77.6M | $-121.3M | ||
| Q2 24 | $67.7M | $-120.4M | ||
| Q1 24 | $45.3M | $-251.2M |
| Q4 25 | 43.8% | 90.5% | ||
| Q3 25 | 43.5% | 86.1% | ||
| Q2 25 | 44.4% | 87.5% | ||
| Q1 25 | 46.1% | 85.2% | ||
| Q4 24 | 45.6% | 85.8% | ||
| Q3 24 | 46.0% | 83.0% | ||
| Q2 24 | 46.2% | 85.1% | ||
| Q1 24 | 45.6% | 83.4% |
| Q4 25 | 12.7% | 12.4% | ||
| Q3 25 | 15.2% | 11.5% | ||
| Q2 25 | 13.4% | 6.7% | ||
| Q1 25 | 15.8% | 1.0% | ||
| Q4 24 | 17.6% | -7.0% | ||
| Q3 24 | 16.9% | -12.0% | ||
| Q2 24 | 16.0% | -11.5% | ||
| Q1 24 | 15.3% | -34.8% |
| Q4 25 | 6.0% | 4.4% | ||
| Q3 25 | 8.7% | 8.8% | ||
| Q2 25 | 6.7% | 7.2% | ||
| Q1 25 | 8.1% | 0.1% | ||
| Q4 24 | 12.0% | -13.5% | ||
| Q3 24 | 9.6% | -12.1% | ||
| Q2 24 | 8.3% | -13.0% | ||
| Q1 24 | 5.9% | -33.4% |
| Q4 25 | $0.33 | $0.05 | ||
| Q3 25 | $0.46 | $0.08 | ||
| Q2 25 | $0.35 | $0.06 | ||
| Q1 25 | $0.41 | $0.00 | ||
| Q4 24 | $0.67 | $-0.10 | ||
| Q3 24 | $0.51 | $-0.09 | ||
| Q2 24 | $0.45 | $-0.09 | ||
| Q1 24 | $0.30 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $360.4M | $4.5B |
| Total DebtLower is stronger | $3.7B | $836.4M |
| Stockholders' EquityBook value | $4.0B | $4.4B |
| Total Assets | $8.4B | $8.2B |
| Debt / EquityLower = less leverage | 0.94× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $360.4M | $4.5B | ||
| Q3 25 | $399.8M | $4.0B | ||
| Q2 25 | $376.8M | $2.8B | ||
| Q1 25 | $340.9M | $2.5B | ||
| Q4 24 | $329.2M | $2.6B | ||
| Q3 24 | $432.1M | $2.7B | ||
| Q2 24 | $320.0M | $2.6B | ||
| Q1 24 | $340.7M | $2.8B |
| Q4 25 | $3.7B | $836.4M | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $4.0B | — | ||
| Q1 25 | $4.0B | — | ||
| Q4 24 | $4.0B | — | ||
| Q3 24 | $4.1B | — | ||
| Q2 24 | $4.1B | — | ||
| Q1 24 | $4.2B | — |
| Q4 25 | $4.0B | $4.4B | ||
| Q3 25 | $3.9B | $4.1B | ||
| Q2 25 | $3.8B | $3.8B | ||
| Q1 25 | $3.7B | $3.5B | ||
| Q4 24 | $3.7B | $3.3B | ||
| Q3 24 | $3.6B | $3.4B | ||
| Q2 24 | $3.5B | $3.4B | ||
| Q1 24 | $3.4B | $3.4B |
| Q4 25 | $8.4B | $8.2B | ||
| Q3 25 | $8.4B | $7.6B | ||
| Q2 25 | $8.4B | $6.3B | ||
| Q1 25 | $8.4B | $5.8B | ||
| Q4 24 | $8.4B | $5.9B | ||
| Q3 24 | $8.5B | $5.8B | ||
| Q2 24 | $8.3B | $5.7B | ||
| Q1 24 | $8.4B | $5.7B |
| Q4 25 | 0.94× | 0.19× | ||
| Q3 25 | 0.99× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.08× | — | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | 1.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.0M | $417.3M |
| Free Cash FlowOCF − Capex | $134.0M | $379.8M |
| FCF MarginFCF / Revenue | 16.3% | 25.4% |
| Capex IntensityCapex / Revenue | 7.0% | 2.5% |
| Cash ConversionOCF / Net Profit | 3.89× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $396.2M | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.0M | $417.3M | ||
| Q3 25 | $249.5M | $402.6M | ||
| Q2 25 | $113.5M | $263.6M | ||
| Q1 25 | $140.4M | $44.1M | ||
| Q4 24 | $176.1M | $75.2M | ||
| Q3 24 | $197.2M | $188.4M | ||
| Q2 24 | $111.2M | $-95.6M | ||
| Q1 24 | $147.2M | $-308.6M |
| Q4 25 | $134.0M | $379.8M | ||
| Q3 25 | $182.8M | $354.5M | ||
| Q2 25 | $47.0M | $219.8M | ||
| Q1 25 | $32.4M | $-12.3M | ||
| Q4 24 | $68.6M | $-17.3M | ||
| Q3 24 | $115.0M | $54.7M | ||
| Q2 24 | $51.9M | $-205.5M | ||
| Q1 24 | $80.6M | $-465.1M |
| Q4 25 | 16.3% | 25.4% | ||
| Q3 25 | 22.6% | 25.1% | ||
| Q2 25 | 5.9% | 16.7% | ||
| Q1 25 | 4.2% | -1.1% | ||
| Q4 24 | 8.1% | -1.5% | ||
| Q3 24 | 14.2% | 5.5% | ||
| Q2 24 | 6.4% | -22.1% | ||
| Q1 24 | 10.4% | -61.9% |
| Q4 25 | 7.0% | 2.5% | ||
| Q3 25 | 8.3% | 3.4% | ||
| Q2 25 | 8.4% | 3.3% | ||
| Q1 25 | 14.0% | 5.0% | ||
| Q4 24 | 12.7% | 8.2% | ||
| Q3 24 | 10.2% | 13.3% | ||
| Q2 24 | 7.3% | 11.8% | ||
| Q1 24 | 8.6% | 20.8% |
| Q4 25 | 3.89× | 6.28× | ||
| Q3 25 | 3.54× | 3.22× | ||
| Q2 25 | 2.15× | 2.79× | ||
| Q1 25 | 2.23× | 34.71× | ||
| Q4 24 | 1.72× | — | ||
| Q3 24 | 2.54× | — | ||
| Q2 24 | 1.64× | — | ||
| Q1 24 | 3.25× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ENTG
| Fabs | $516.3M | 63% |
| Equipment And Engineering | $121.8M | 15% |
| Chemical And Materials | $83.8M | 10% |
| Other | $61.7M | 7% |
| Non Semi | $40.3M | 5% |
ONC
Segment breakdown not available.
